Agravitae Publishes Graviola Extract Study, Validating 4.09% Active Ingredient Concentration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy ?
Source: Globenewswire
- Transparency Enhancement: Agravitae's collaboration with Cambium Analytica has resulted in the publication of an analytical study on graviola extract, validating a 4.09% concentration of active ingredients, thereby addressing the market's transparency gap in botanical supplements.
- Extraction Method Optimization: The research indicates that using 100% ethanol with sonication yields the highest concentration of annonacin at 0.524%, demonstrating ethanol's effectiveness in extracting bioactive compounds from graviola leaves, which enhances the product's market competitiveness.
- Leaf Maturity Impact: The study reveals that young graviola leaves contain twice the concentration of active compounds compared to mature leaves, at 0.533% and 0.251% respectively, emphasizing the critical influence of plant part selection on product quality consistency and efficacy.
- Industry Benchmark Establishment: Agravitae's research sets a benchmark for standardization in graviola extract products, promoting compliance and transparency in the botanical supplement market, thereby enhancing consumer trust in the brand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
